243 related articles for article (PubMed ID: 32855386)
21. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
22. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
24. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
Lo Russo G; Moro M; Sommariva M; Cancila V; Boeri M; Centonze G; Ferro S; Ganzinelli M; Gasparini P; Huber V; Milione M; Porcu L; Proto C; Pruneri G; Signorelli D; Sangaletti S; Sfondrini L; Storti C; Tassi E; Bardelli A; Marsoni S; Torri V; Tripodo C; Colombo MP; Anichini A; Rivoltini L; Balsari A; Sozzi G; Garassino MC
Clin Cancer Res; 2019 Feb; 25(3):989-999. PubMed ID: 30206165
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
[TBL] [Abstract][Full Text] [Related]
26. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
27. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
28. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
29. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Du P; Hu T; An Z; Li P; Liu L
Cancer Sci; 2020 Jun; 111(6):1887-1898. PubMed ID: 32227409
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
32. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
33. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
36. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
37. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
Gong B; Kiyotani K; Sakata S; Nagano S; Kumehara S; Baba S; Besse B; Yanagitani N; Friboulet L; Nishio M; Takeuchi K; Kawamoto H; Fujita N; Katayama R
J Exp Med; 2019 Apr; 216(4):982-1000. PubMed ID: 30872362
[TBL] [Abstract][Full Text] [Related]
38. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
39. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
40. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]